Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:JAZZ 25 August 2025 - 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
17 November 2025
···
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks reported its Phase 3 HERIZON-GEA-01 trial showed Ziihera (zanidatamab-hrii) combinations outperformed trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The triple-combination arm also improved overall survival. Jazz Pharmaceuticals plans to file for FDA approval in the first half of 2026. ZYME shares jumped 30–50% pre-market on the news.
17 November 2025
····
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes will acquire Avadel for $18.50 per share in cash, plus a $1.50 contingent payout, valuing the deal at about $2.1 billion. Avadel’s LUMRYZ sales are projected at $265–$275 million in 2025, with 3,100 patients on therapy. AVDL shares surged to near a 52-week high after the Jazz settlement and Alkermes news. Halper Sadeh LLC is investigating whether the offer undervalues Avadel.
22 October 2025
·····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

The U.S. administration fired CDC Director Dr. Susan Monarez after she resisted Health Secretary Robert F. Kennedy Jr.’s directives; four senior CDC officials resigned in protest, citing risks to young Americans and pregnant women. U.S. regulators approved updated COVID-19 vaccines for fall, but limited routine access to adults 65+ and high-risk groups, excluding healthy under-65s.
28 August 2025
····
FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

FDA Shockers, Breakthrough Trials & Outbreak Alerts – Biotech & Health News Roundup (Aug 24–25, 2025)

The FDA approved Ionis’ Dawnzera as the first RNA-targeted preventive treatment for hereditary angioedema, after trials showed an 81% drop in attack rates. Regulators rejected PTC Therapeutics’ vatiquinone for Friedreich’s ataxia, citing insufficient efficacy data and requesting another trial. Jazz Pharmaceuticals secured approval for dordaviprone to treat rare pediatric brain tumors.
25 August 2025
······

Stock Market Today

  • Palantir's Sky-High Valuation Reflects Robust AI Optimism, Heightening Risk
    April 9, 2026, 3:40 PM EDT. Palantir Technologies (PLTR) is trading at valuations signaling very high investor expectations, with trailing and forward price-to-earnings multiples exceeding 238 and 95 times respectively. Its price-to-sales ratios surpass 80 and 42 times, far above sector peers like Snowflake (below 11 and 9 times) and Datadog, underscoring a steep premium on Palantir's AI and data analytics leadership. Such rich valuation multiples imply the market forecasts rapid revenue growth and improved profits, but also leave little margin for error. Any growth misses or margin setbacks could prompt sharp share price declines. Despite strong demand for AI and increasing commercial clientele, investors are advised caution given the stretched valuation compared to comparable tech companies.

Latest article

Mortgage Rates Today: 30-Year Fixed Falls to 6.37% After Five-Week Climb (Freddie Mac)

Mortgage Rates Today: 30-Year Fixed Falls to 6.37% After Five-Week Climb (Freddie Mac)

9 April 2026
The average 30-year fixed mortgage rate fell to 6.37% from 6.46%, Freddie Mac said Thursday. Purchase mortgage applications rose 1% last week but remained 7% lower than a year ago, according to the Mortgage Bankers Association. Refinance activity dropped 3%. Mortgage News Daily’s index showed the 30-year fixed at 6.38%, with the 10-year Treasury near 4.27%.
Bitcoin Price Today: Why BTC Is Stuck Between Ceasefire Relief and ETF Doubts

Bitcoin Price Today: Why BTC Is Stuck Between Ceasefire Relief and ETF Doubts

9 April 2026
Bitcoin traded near $72,000 Thursday, up 0.3%, after earlier slipping on renewed Middle East tensions. U.S. spot bitcoin ETFs saw $471.4 million in inflows April 6 but $93.9 million in outflows April 8, as Morgan Stanley’s new MSBT fund debuted with $30.6 million. Ether fell 0.9% to $2,210.56. Bitcoin remains 43% below its October 2025 record high.
Silver Price Today Jumps Toward $76 as Dollar Slides and Iran Ceasefire Wobbles

Silver Price Today Jumps Toward $76 as Dollar Slides and Iran Ceasefire Wobbles

9 April 2026
Spot silver jumped 2.9% to $76.24 an ounce Thursday, extending gains after a U.S.-Iran ceasefire and a weaker dollar. Gold rose 1.63% to $4,793.07. Analysts warned the truce remains fragile, with markets watching for March U.S. inflation data due Friday. Oil fell below $100 but tensions persisted in the Middle East.
Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

Gold Price Today: Bullion Jumps as Dollar Slips and Fragile Iran Truce Keeps CPI in Focus

9 April 2026
Spot gold rose 1.6% to $4,789.67 an ounce by 1:30 p.m. ET Thursday as the U.S. dollar weakened and Treasury yields slipped. U.S. gold futures settled 0.9% higher at $4,818.00. Traders watched a fragile ceasefire between Washington and Tehran and awaited Friday’s U.S. inflation data. March saw gold’s steepest monthly drop since 2008, according to China’s central bank.
Go toTop